Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Inclusion Criteria: * Subjects with end stage renal disease on hemodialysis * Post-dialysis body weight \>45.0 kg * BMI between 18.0 and 40.0 kg/m2 (inclusive) Exclusion Criteria: * Subjects with positive test results for HBsAg (hepatitis B surface antigen), HCV antibody or HIV antibody * Subjects with known history of liver failure or liver surgery * Subjects with a history or current clinically significant chronic or acute blood loss